0001193125-26-204944
SEC filingIDEAYA Biosciences reported Q1 2026 financial results with $973M cash runway into 2030 unchanged and announced OptimUM-02 trial met primary endpoint, enabling H2 2026 NDA submission for darovasertib combination in mUM.
IDEAYA Biosciences delivered a pivotal Q1 2026 update, headlined by the OptimUM-02 Phase 2/3 trial success for darovasertib plus crizotinib in first-line HLAA2-negative metastatic uveal melanoma. The combination slashed progression risk by 58% (HR 0.42, 95% CI 0.30-0.59, p<0.0001), extending median PFS to 6.9 months from 3.1 months versus investigator's choice, with ORR of 37.1% including 5 complete responses. This positions the first NDA submission under FDA's RTOR program in H2 2026 for potential accelerated approval, with full data at ASCO 2026. CEO Yujiro S. Hata called it transformational, highlighting a catalyst-rich H2 including OptimUM-01 data in HLAA2-positive mUM and updates for IDE849, IDE034, IDE892, and IDE574. Financially, cash reserves of $972.9M as of March 31 provide runway into 2030 despite a Q1 net loss of $98.5M, driven by elevated R&D at $95.7M (up from $86.6M prior quarter) for pipeline acceleration and G&A at $19.4M for commercial prep. Collaboration revenue dipped to $6.6M from Servier darovasertib deal, with $155.3M remaining deferred. Strategic moves include IDE849 registrational trial initiation by year-end, AstraZeneca combo collab, and new CDO Dr. Theo Ross to steer early pipeline. Deprioritizing IDE275/IDE705 post-GSK termination refocuses resources on high-potential synthetic lethality and ADC programs.